Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax

ClinicalTrials.gov ID

NCT07691047

Lead Sponsor

Private Hospital of Confluent, FranceOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

130Estimated

Last Update Posted

Jul 8, 2026Actual

Start Date

Jul 31, 2026Estimated

Primary Completion Date

Jul 31, 2029Estimated

Completion Date

Sep 30, 2029Estimated

Official Title

Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax

Brief Summary

Chronic lymphocytic leukemia is a malignant blood disorder characterized by the proliferation of abnormal B lymphocytes in the blood, lymph nodes, and bone marrow. It generally occurs after age 70 and is the fourth most common blood cancer in France, following multiple myeloma, diffuse large B-cell lymphoma, and myelodysplastic syndromes.

Treatments have advanced since 2015 with the introduction of immunotherapy and targeted therapies. The BCL2 inhibitor (venetoclax) is one of these innovative treatments. It is recommended as first-line therapy and for relapse in combination with anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase inhibitors. Early studies showed that initial administration of venetoclax as monotherapy could lead to lysis syndrome as early as the first few days of treatment. This risk was correlated with the venetoclax dose and tumor burden. Prevention guidelines were subsequently proposed to guide management. This risk is therefore assessed before treatment begins (low, moderate, high), based on lymph node size and circulating lymphocyte count.

For patients at moderate and high risk, a treatment strategy is recommended that includes hyperhydration and uric acid-lowering agents, which may require hospitalization in some cases. The introduction of combination therapies has improved the depth and duration of response (obinutuzumab + venetoclax and ibrutinib + venetoclax). Venetoclax is added after the initiation of partner agents (22 days after obinutuzumab and 3 cycles after ibrutinib). This initial phase of treatment may reduce the risk of hemolytic syndrome. We propose here to reassess the risk of hemolytic syndrome before starting venetoclax in order to simplify management.

• Chronic Lymphoid Leukemia

• Cervical, Thoracic, Abdominal, and Pelvic CT Scan

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients with chronic lymphocytic leukemia/lymphocytic lymphoma
• Meeting the treatment criteria according to iwCLL 2018
• Eligible for treatment with venetoclax in combination with a Bruton's tyrosine kinase inhibitor (ibrutinib, other approved generations) or obinutuzumab
• First-line treatment or relapse

Exclusion Criteria:

• Patients with meningeal and/or cerebral involvement
• Patients with an active, uncontrolled infection
• Patients scheduled to receive venetoclax monotherapy or rituximab-venetoclax according to the MURANO study regimen (Murano regimen: venetoclax is administered before rituximab)
• Contraindications to contrast-enhanced CT scanning (severe renal insufficiency, documented allergy to contrast agents).
• Pregnancy or breastfeeding
• Individuals deprived of their liberty, under legal guardianship, or under conservatorship
• Dementia, mental impairment, or psychiatric disorder that could compromise the patient's ability to provide informed consent and/or to adhere to the protocol and follow-up requirements of the trial

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Private Hospital of Confluent, FranceOTHER

drc@vivalto-sante.com+33 6 78 27 76 72

• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT06428019

  RecruitingInterventionalPhase 3Updated Apr 9, 2026
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  NCT04895436

  RecruitingInterventionalPhase 2Updated Feb 9, 2026
• Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

  NCT03310190

  CompletedObservationalUpdated Mar 30, 2023
• Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

  NCT03422393

  Active, not recruitingInterventionalPhase 1Updated Jul 5, 2024
• A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT02966756

  Active, not recruitingInterventionalPhase 2Updated Aug 19, 2026
• Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens

  NCT04790045

  Not yet recruitingInterventionalPhase 4Updated Oct 3, 2023